降纤酶质量研究

来源 :中国药师 | 被引量 : 0次 | 上传用户:Heavenws
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
目的:考察降纤酶的质量现状及存在问题。方法:对国家食品药品监督管理总局(CFDA)网站数据库上检索到的有降纤酶生产批文的生产企业进行问卷调查,对部分生产企业进行现场调研,针对上述两个环节中发现的问题,对降纤酶原液、中间体、半成品、成品开展了降纤酶原料(液)蛋白质序列分析等一系列实验室探索性研究,提升其安全性、有效性、稳定性和可控性。结果:目前市场上流通的大部分样品的纯度均较低,其中尖吻蝮蛇降纤酶的主要成分为蕲蛇酶,白眉蝮蛇降纤酶的主要成分为NCBI蛋白数据库中编号为gi|143681919|(sp|P85109.1|)的蛋白;降纤酶效价测定影响因素中Tris的浓度影响最大;加入大分子保护剂可以改善样品中的辅料右旋糖酐对效价测定结果的影响。效价测定中两种仪器法(磁珠法和光学法)测定的结果差距较大,均比目测法低,目前尚不适用于降纤酶效价的测定。热稳定性表明注射用降纤酶热稳定性较好,降纤酶注射液的热稳定性较差。本研究采用浓缩一倍的Tris缓冲液稀释纤原,并加入适当的保护剂,建立了降纤酶半成品效价测定的方法。结论:目前降纤酶的质量有待提高。两种蛇毒来源的降纤酶结构、纯度等差别较大,现行的标准项目设置不全面;缺少专属性较强目前的鉴别;异常毒性、效价测定可操作性差等,不能有效地控制降纤酶的质量。有必要将尖吻蝮蛇和白眉蝮蛇来源的降纤酶作为两个品种管理,同时加强降纤酶的标准化研究。 Objective: To investigate the quality of defibrase and its existing problems. Methods: A questionnaire survey was conducted among the manufacturing enterprises with defibrase production approval retrieved from the database of CFDA website. Some production enterprises were investigated on site. According to the problems found in the above two links, Fibrinogen, intermediates, semi-finished products and finished products have carried out a series of laboratory exploratory studies on the protein sequence analysis of defibrase (raw material) to improve their safety, effectiveness, stability and controllability. Results: The purity of most samples circulating in the market was low at present. The main component of Agkistrodon halysii defibrase was Acutobin, the main component of Agkistrodon halysii defibrase was NCI protein database named gi | 143681919 | (sp | P85109.1 |) protein; defibrase titer in the determination of the most influential factors Tris concentration; addition of a large molecule protective agent can improve the sample dextran accessories on the titer results. The determination of titer between the two instrument method (magnetic bead method and optical method) the results of the larger gap, both lower than the visual method, is not currently suitable for the determination of defibrase titer. Thermal stability shows that defibrase for injection has better thermal stability and defibrase is less stable. In this study, the use of concentrated double dilution of Tris buffer fibrillar fibroin, and adding appropriate protective agent, established defibrase semi-finished product titer method. Conclusion: At present, the quality of defibrase is to be improved. Two kinds of snake venom defibrase source from the structure, purity and other large differences, the current standard project settings are not comprehensive; the lack of specificity of the current identification; abnormal toxicity, potency determination operability is poor, can not effectively control the defibrillators Enzyme quality. It is necessary to manage the defibrillators from Agkistrodon acutus and Agkistrodon acutus as two breeds and to standardize defibrase.
其他文献
[目的]探讨突发性群体颅脑外伤的抢救与护理组织管理.[方法]成立急救小组与管理组织,抢救分区,合理安排人力对实施紧急救治.[结果]抢救24例群体颅脑外伤患者,治愈16例,好转7
[目的]观察奥扎格雷钠对急性脑梗死患者一氧化氮(NO)及凝血功能的影响.[方法]选择急性脑梗死患者64例,按就诊顺序分为治疗组34例和对照组30例,对照组予常规西医治疗,治疗组在
[目的]总结颅内外高流量搭桥联合动脉瘤孤立术治疗复杂型动脉瘤的围手术期护理经验.[方法]对本院神经外科8例颅内外高流量搭桥联合动脉瘤孤立术治疗的复杂型颅内动脉瘤患者,
[目的]探讨妊娠合并重症急性胰腺炎(SAP)的护理措施.[方法]回顾性分析11例妊娠合并重症急性胰腺炎患者的临床资料.[结果]本组11例患者中,痊愈9例,好转2例,孕妇、胎儿无一例死
[目的]总结腹腔镜辅助下手术治疗小儿腹腔淋巴管瘤的临床经验.[方法]回顾性分析2005~2009年本院11例腹腔镜辅助下手术治疗腹腔淋巴管瘤患儿的临床资料.[结果]患儿的最主要临床
粒细胞肉瘤是发生于髓外由未成熟髓系细胞构成的局限性肿瘤,较少见,现将本院遇到的一例报道如下.1 病例资料患者,女,15岁,因双下肢乏力2个月,右上腹痛1周入院.患者于2个月前
[目的]探讨鼻内窥镜下鼻腔泪囊吻合术治疗慢性泪囊炎的护理体会.[方法]对28例慢性泪囊炎患者行鼻内窥镜下鼻腔泪囊吻合术,术前进行心理护理和健康指导,术后加强术侧眼部及鼻
[目的]探讨清胰汤干预早期急性重症胰腺炎的时机及护理策略.[方法]本研究前瞻性地将61例重症胰腺炎患者随机分为两组,A组积极抗休克,循环稳定后经胃管注入清胰汤;B组纠正休克
1 病历患者,女,54岁,因突发右上腹疼痛8 h于2011年7月18日入院.入院体查皮肤巩膜无黄染,右上腹压痛,无反跳痛,murphys征阳性.血常规白细胞9.6×109/L,中性粒细胞0.92,B超及CT
1 病历资料患者,男性,5岁,因反复发热4个月,伴神志不清2个月于2009年1月29日入院.家属代诉患儿于4个月前无明显诱因出现高热,当时神志清楚,到本厂职工医院予以退热处理,效果